Kaken Pharmaceutical Co., Ltd.
Research Kaken Pharmaceutical Co., Ltd. (4521.T) on Bullrun: market cap JPY 145.60B, P/E 68.2, dividend yield 4.9%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4521.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyJPY
- Market capJPY 145.60B
- P/E68.2
- Dividend yield4.9%
- Financial periodFY2026
- RevenueJPY 76.87B
- Revenue growth-18.3%
- Net incomeJPY 2.14B
- Free cash flow-JPY 16.50B
- Gross margin52.0%
Valuation Snapshot
latest market cap is JPY 145.60B; P/E is 68.2; dividend yield is 4.9%.
Peer valuation comparison
Latest P/E is 68.16x versus a Healthcare sector median of 21.69x (214.2% above).
Latest dividend yield is 4.94% versus a Healthcare sector median of 2.41% (105.0% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 76.87B | JPY 2.14B | -JPY 16.50B | 52.0% | 56.57 | JPY 44.71B | JPY 3.85B | JPY 147.62B |
| FY2025 | JPY 94.04B | JPY 13.95B | JPY 25.39B | 62.2% | 365.42 | JPY 54.09B | JPY 3.85B | JPY 152.63B |
| FY2024 | JPY 72.04B | JPY 8.03B | JPY 410.00M | 53.5% | 212.67 | JPY 50.63B | JPY 3.85B | JPY 143.76B |
| FY2023 | JPY 72.98B | JPY 5.44B | JPY 7.05B | 54.2% | 144.8 | JPY 59.56B | JPY 3.85B | JPY 136.26B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 145.60B | 68.2 | 4.9% | 190 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 190 JPY, yield 4.9%.
| Year | Dividends/share |
|---|---|
| FY2026 | 190 JPY |
| FY2025 | 170 JPY |
| FY2024 | 190 JPY |
| FY2023 | 150 JPY |
About Kaken Pharmaceutical Co., Ltd.
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kaken Pharmaceutical Co., Ltd.'s market cap?
Kaken Pharmaceutical Co., Ltd.'s market capitalization is JPY 145.60B.
What is Kaken Pharmaceutical Co., Ltd.'s P/E ratio?
Kaken Pharmaceutical Co., Ltd.'s price-to-earnings (P/E) ratio is 68.2.
Does Kaken Pharmaceutical Co., Ltd. pay a dividend?
Kaken Pharmaceutical Co., Ltd. has a dividend yield of 4.9%.
What does Kaken Pharmaceutical Co., Ltd. do?
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally.